Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 and CD22 CAR T-cell Therapy vs CD19 CAR T-cell Bridging to HSCT in r/r B-ALL
NCT06343090Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2042
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label trial of CD19 CAR T-cell (Beijing GoBroad Hospital) and CD22-CAR-T in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Beijing Gaobo Hospital. Primary endpoint: Event-Free Survival at 2 years. Started Apr 2024; status: recruiting.
02
Drugs
CD19 CAR T-cell (Beijing GoBroad Hospital)CD22-CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06343090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343090.